Grail’s $900M Haul, Kite’s CAR-T Stands Up 6 Months, & Icahn Returns

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.